[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641318":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":35,"responsibleParty":40,"collaborators":35,"id":42,"slug":35,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":35,"enrollmentInfo":52,"targetDuration":35,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":72,"whyStopped":35,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":35},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HIV-1-Infected Participants Receiving Suppressive Antiretroviral Therapy","EXPERIMENTAL","Participants living with HIV-1 receiving suppressive antiretroviral therapy (ART) and undergoing clinically indicated colonoscopy will undergo blood sampling and additional colonic mucosal biopsies for immunological and virological analyses.",[13],"Procedure: Colonic Mucosal Biopsies",{"label":15,"type":10,"description":16,"interventionNames":17},"HIV-Seronegative Controls","HIV-seronegative participants undergoing clinically indicated colonoscopy will undergo blood sampling and additional colonic mucosal biopsies for immunological analyses.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Colonic Mucosal Biopsies","Collection of blood samples and additional colonic mucosal biopsies during clinically indicated colonoscopy for immunological and virological analyses.",[9,15],[25],"Blood Sampling",[27],{"name":28,"affiliation":29,"role":30},"Pierre Delobel, MD, PhD","University Hospital of Toulouse","PRINCIPAL_INVESTIGATOR",[32,37],{"name":28,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+33 5 61 77 75 08",null,"delobel.p@chu-toulouse.fr",{"name":38,"role":33,"phone":35,"phoneExt":35,"email":39},"Marcia Trumeau, MS","marcia.trumeau@anrs.fr",{"type":41,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100641318",false,"NCT07656077","Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy","Intestinal Tissue-Resident Memory T Cells in HIV-1 Infection: Mechanisms Involved in Their Depletion and Role in Viral Persistence During Antiretroviral Therapy","ANRSGALT-2","I - Inclusion criteria\n\n1 - Group 1: People Living With HIV-1\n\n* Age ≥ 18 years\n* Documented HIV-1 infection\n* Continuous suppressive antiretroviral therapy initiated during chronic infection for at least 12 months\n* Plasma HIV-1 RNA ≤ 50 copies\u002FmL for at least 6 months under ART (one isolated blip ≤ 200 copies\u002FmL allowed)\n* Blood CD4+ T-cell count ≥ 350 cells\u002Fmm³\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\n  2- Group 2: HIV-Seronegative Controls\n* Age ≥ 18 years\n* HIV-seronegative status\n* Clinically indicated colonoscopy independent of the research protocol\n* Affiliation with a social security system\n* Written informed consent obtained before any study-specific procedure\n\nII - Exclusion Criteria\n\n1. Group 1: People Living With HIV-1\n\n   * HIV-2 infection\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Participation in an HIV vaccine or immunotherapy study\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty\n2. Group 2: HIV-Seronegative Controls\n\n   * HIV-1 or HIV-2 infection\n   * Refusal to undergo HIV serology testing\n   * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease\n   * Platelet count \\\u003C 50 G\u002FL or uncorrectable coagulation disorders contraindicating biopsies\n   * Decompensated cirrhosis\n   * History of lymphoma\n   * Pregnant or breastfeeding women\n   * Participation in another clinical study with an ongoing exclusion period\n   * Vulnerable individuals, including minors, individuals under guardianship, or persons deprived of liberty",true,"ALL","18 Years",{"count":53,"type":54},30,"ESTIMATED","INTERVENTIONAL",[57],"NA","The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.",[60,61,62],"HIV-1 Infection","HIV Reservoir","Antiretroviral Therapy",[64,65,66,67,68,69,70,71],"HIV-1","Tissue-Resident Memory T Cells","Viral Reservoir","ART","Intestinal Mucosa","Mucosal Immunity","CD4 T Cells","HIV Persistence","NOT_YET_RECRUITING","2026-06-14",{"date":75,"type":76},"2026-06-18","ACTUAL",{"date":78,"type":54},"2026-08-01",{"date":80,"type":54},"2030-07-31",{"name":5,"class":6}]